Despite promising clinical evidence, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering considerable difficulty from pharmacy benefit managers. The organizations are frequently erecting obstacles to access, including steep expense criteria and prior authorization that hinder patient opportun